Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on April 10, 2025
c/side Launches Channel Partner Program as Zero-Day Web Dependency Attacks—and Compliance Pressure—Accelerate
GlobeNewswire
·
April 10, 2025
Third-party web scripts are now the #1 source of web-based data breaches Most companies do not even know which scripts are running on their site PCI DSS 4.0.1 mandates new protections starting March 2025—non-compliance means fines, or worse SAN FRANCISCO, …
Spirit Digital AG Confirms Ticker Listings for Ethereum and Solana Yield+ ETPs on SIX and Deutsche Börse
GlobeNewswire
·
April 10, 2025
Zug, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Spirit Digital AG (“Spirit”), a wholly owned subsidiary of Spirit Blockchain Capital Inc. (CSE:SPIR / OTC:SPBCF / FRA:RTFB), helping advance digital asset finance through thoughtful innovation, is …
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
GlobeNewswire
·
April 10, 2025
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that …
Evaxion to present at World Vaccine Congress
GlobeNewswire
·
April 10, 2025
Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two …
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
GlobeNewswire
·
April 10, 2025
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites …
Eviden signs a 50-million-euro contract to build Serbia’s National AI Factory
GlobeNewswire
·
April 10, 2025
Eviden will bring together a unique comprehensive set of AI capabilities – supercomputing power for AI, software layer and AI use-cases development Paris, France – April 10, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and …
Eviden signe un contrat de 50 millions d'euros pour développer une « AI Factory » nationale en Serbie
GlobeNewswire
·
April 10, 2025
Eviden fournira un ensemble complet et unique de capacités d'IA associant puissance de supercalcul, couche logicielle et développement de cas d’usage d’IA Paris, France – 10 avril 2025 – Eviden, la ligne d’activités du groupe Atos leader dans le digital, …
Advanced PMIC for High-Performance AI, Industrial Computing and Data Center Applications
GlobeNewswire
·
April 10, 2025
CHANDLER, Ariz., April 10, 2025 (GLOBE NEWSWIRE) -- The rapid integration of AI into industrial, computing and data center applications is fueling a growing demand for more efficient and advanced power management solutions. Microchip Technology (Nasdaq: …
Vertex baut sein Chief Strategy Office aus, um e-Invoicing und globale Compliance-Initiativen voranzutreiben
GlobeNewswire
·
April 10, 2025
KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX), ein globaler Anbieter von Technologielösungen für indirekte Steuern, gab heute die Erweiterung seines Chief Strategy Office (CSO) bekannt: Christopher Hall und Kathya …
Vertex Expands Chief Strategy Office to Advance E-Invoicing and Global Compliance Initiatives
GlobeNewswire
·
April 10, 2025
KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, today announced the expansion of its Chief Strategy Office (CSO) with the addition of …
Avalyn to Participate in Upcoming Investor Conference in April
GlobeNewswire
·
April 10, 2025
CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management will …
Global Clean Technology Innovators Honored in 2025 CleanTech Breakthrough Awards Program
GlobeNewswire
·
April 10, 2025
LOS ANGELES, April 10, 2025 (GLOBE NEWSWIRE) -- CleanTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout climate and clean technology companies, products and services around the globe, today …
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
GlobeNewswire
·
April 10, 2025
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy …
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
GlobeNewswire
·
April 10, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need …
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire
·
April 10, 2025
– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a patient survey conducted in partnership with the National …
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
GlobeNewswire
·
April 10, 2025
Dansey, a former senior executive at Pfizer and Seagen, Inc., brings extensive experience in immuno-oncology and drug development Board appointment reinforces Company’s commitment to advancing Jankistomig, a one-of-a-kind PD-1/VEGFR2 dual paratopic …
Byrna Technologies Fiscal First Quarter 2025 Results
GlobeNewswire
·
April 10, 2025
ANDOVER, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security …
Cerence AI Honored with HARMAN's Best Technology Award
GlobeNewswire
·
April 10, 2025
BURLINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that it has been awarded the Best Technology Award by HARMAN during its …
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
GlobeNewswire
·
April 10, 2025
A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in Indonesia and Australia – catalysts for revenue in 2026 …
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
GlobeNewswire
·
April 10, 2025
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking …